Lacosamide

Generic Name: Lacosamide

Brand Names: Motpoly, Vimpat, Lacosamide Adroiq, Lacosamide Accord, Lacosamide UCB

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₈N_₂O_₃

CAS Number: 175481-36-4

Unique Ingredient Identifier: 563KS2PQY5

Background: Lacosamide is a functionalized amino acid that has activity in the maximal electroshock seizure test, and is indicated for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain. Recent studies indicate that Lacosamide only affects those neurons which are depolarized or active for long periods of time, typical of neurons at the focu...

Indication: Lacosamide is indicated for the treatment of partial-onset seizures in patients aged one month and older and as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients aged four years and older.

Associated Conditions: Epilepsy, Primary Generalized Tonic-Clonic Seizures, Partial-Onset Seizures, Status Epilepticus

Associated Therapies: -

Clinical Trials

A Trial to Evaluate the Long Term Safety and Tolerability of Lacosamide Taken as Monotherapy in Adults With Partial-onset Seizures

Phase 3

Completed

Conditions: Epilepsy
Partial-onset Seizures

Interventions: Drug: Lacosamide

First Posted Date: 2014-04-28

Last Posted Date: 2019-10-28

Lead Sponsor: UCB Japan Co. Ltd.

Target Recruit Count: 19

Registration Number: NCT02124564

Locations: 🇯🇵
6, Kagoshima, Japan
🇯🇵
7, Kamakura, Japan
🇯🇵
11, Itami, Japan

and more 8 locations

A Study to Investigate the Safety and Efficacy of Lacosamide Added to the Patients Current Therapy in Patients Aged 1 Month to Less Than 18 Years Old With Epilepsy Syndromes Associated With Generalized Seizures.

Phase 2

Completed

Conditions: Epilepsy

Interventions: Drug: Lacosamide

First Posted Date: 2013-10-25

Last Posted Date: 2019-05-07

Lead Sponsor: UCB Pharma

Target Recruit Count: 55

Registration Number: NCT01969851

Locations: 🇺🇸
112, Hackensack, New Jersey, United States
🇺🇸
101, Orlando, Florida, United States
🇫🇷
309, Ile-De-France, France

and more 15 locations

A Clinical Study to Investigate the Efficacy and Safety of Lacosamide as an Add on Therapy in Children With Epilepsy With Partial-onset Seizures

Phase 3

Completed

Conditions: Epilepsy

Interventions: Drug: Lacosamide

First Posted Date: 2013-10-17

Last Posted Date: 2022-10-25

Lead Sponsor: UCB BIOSCIENCES, Inc.

Target Recruit Count: 540

Registration Number: NCT01964560

Locations: 🇵🇱
Ep0034 431, Krakow, Poland
🇵🇱
Ep0034 422, Krakow, Poland
🇵🇱
Ep0034 433, Gdansk, Poland

and more 138 locations

Study to Investigate Lacosamide as Add-on Therapy in Subjects ≥4 Years to <17 Years of Age With Partial Onset Seizures

Phase 3

Completed

Conditions: Epilepsy

Interventions: Other: Placebo
Drug: Lacosamide

First Posted Date: 2013-08-13

Last Posted Date: 2018-07-18

Lead Sponsor: UCB Pharma

Target Recruit Count: 404

Registration Number: NCT01921205

Locations: 🇨🇴
172, Floridablanca, Colombia
🇵🇱
430, Warszawa, Poland
🇵🇱
420, Kielce, Poland

and more 115 locations

Safety and Tolerability of Lacosamide in Patients With Gain-of-function Nav1.7 Mutations Related Small Fiber Neuropathy

Phase 3

Completed

Conditions: Small Fiber Neuropathy

Interventions: Drug: Placebo
Drug: Lacosamide

First Posted Date: 2013-07-30

Last Posted Date: 2018-01-10

Lead Sponsor: Academisch Ziekenhuis Maastricht

Target Recruit Count: 25

Registration Number: NCT01911975

Locations: 🇳🇱
Maastricht University Medical Center, Maastricht, Netherlands

Observational Retrospective Study of Effectivity and Tolerability in Patients With Lacosamide Medication

Completed

Conditions: Epilepsy

Interventions: Drug: lacosamide

First Posted Date: 2013-05-21

Last Posted Date: 2013-05-21

Lead Sponsor: Instituto de Investigacion Sanitaria La Fe

Target Recruit Count: 860

Registration Number: NCT01858870

Locations: 🇪🇸
Iis la Fe, Valencia, Spain

Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Adjunctive Therapy With Lacosamide in Adults With Partial-onset Seizures

Phase 3

Completed

Conditions: Epilepsy
Partial-onset Seizures

Interventions: Drug: Lacosamide

First Posted Date: 2013-04-15

Last Posted Date: 2021-08-17

Lead Sponsor: UCB Pharma SA

Target Recruit Count: 473

Registration Number: NCT01832038

Locations: 🇨🇳
86019, Jinan, China
🇨🇳
86004, Kunming, China
🇨🇳
86012, Nanchang, China

and more 64 locations

Lacosamide IV and EEG/EKG (LIVE) Study

Phase 2

Terminated

Conditions: Focal Epilepsy

Interventions: Drug: Lacosamide

First Posted Date: 2012-11-12

Last Posted Date: 2016-09-26

Lead Sponsor: Lawson Health Research Institute

Target Recruit Count: 72

Registration Number: NCT01724918

Locations: 🇨🇦
London Health Sciences Centre, London, Ontario, Canada
🇨🇦
Foothills Medical Center, Calgary, Alberta, Canada
🇨🇦
Toronto Western Hospital, Toronto, Ontario, Canada

and more 1 locations

Study Evaluating Changes in Total Drug Load and Seizure Frequency Using Vimpat® (Lacosamide) in Combination Therapy

Completed

Conditions: Focal Epilepsy With and Without Secondary Generalization

Interventions: Drug: Lacosamide

First Posted Date: 2012-08-27

Last Posted Date: 2016-11-15

Lead Sponsor: UCB Pharma GmbH

Target Recruit Count: 315

Registration Number: NCT01673282

Locations: 🇩🇪
17, Osnabrück, Germany
🇩🇪
14, Radeberg, Germany
🇩🇪
13, Kehl-Kork, Germany

and more 39 locations

Systematic Review: Retigabine for Adjunctive Therapy in Partial Epilepsy

Completed

Conditions: Epilepsy

Interventions: Drug: retigabine/ezogabine
Drug: lacosamide
Drug: zonisamide
Drug: pregabalin
Drug: eslicarbazepine

First Posted Date: 2012-04-30

Last Posted Date: 2013-09-16

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 6498

Registration Number: NCT01587339

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy